Hua-Zhuo-Jie-Du formula alleviates colitis-associated colorectal cancer via regulating phosphatidylinositol 3-kinase/protein kinase B signaling pathway

Figure 5 Hua-Zhuo-Jie-Du formula-containing serum inhibited cell viability, proliferation, migration, and the phosphatidylinositol 3-kinase/protein kinase B signaling pathway in vitro. A: Effects of varying concentrations of Hua-Zhuo-Jie-Du formula (HZJDF)-containing serum on the viability of HT-29 cells; B: Effects of varying concentrations of HZJDF-containing serum on the viability of HCT116 cells; C: Effects of HZJDF-containing serum on the clonogenic ability of HT-29 and HCT116 cells; D: Quantitative assessment of the quantity of HT-29 cell clones generated in each group; E: Quantitative assessment of the quantity of HCT116 cell clones generated in each group; F: Effect of HZJDF-containing serum on the migratory capacity of HT-29 cells; G: Quantitative assessment of the wound-healing area in each group; H: Expressions of proteins associated with the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway in HT-29 cells detected by Western blot analysis; I: Quantitative analysis of the expression levels of phosphorylated-PI3K (p-PI3K)/PI3K in HT-29 cells; J: Quantitative analysis of the expression levels of phosphorylated-AKT (p-AKT)/AKT in HT-29 cells; K: Expressions of proteins associated with the PI3K/AKT signaling pathway in HCT116 cells detected by Western blot analysis; L: Quantitative analysis of the expression levels of p-PI3K/PI3K in HCT116 cells; M: Quantitative analysis of the expression levels of p-AKT/AKT in HCT116 cells. β-actin was utilized as a loading control. Data are shown as the mean ± SD. ^aP < 0.05 vs 0% Hua-Zhuo-Jie-Du formula group. ^bP < 0.01 vs 0% Hua-Zhuo-Jie-Du formula group. HZJDF: Hua-Zhuo-Jie-Du formula; PI3K: Phosphatidylinositol 3-kinase; p-PI3K: Phosphorylated-phosphatidylinositol 3-kinase; AKT: Protein kinase B; p-AKT: Phosphorylated-protein kinase B.